CDC committee recommends opting for Pfizer or Moderna over J&J if given choice
The CDC's advisory committee recommended Thursday that people who have a choice should get an mRNA vaccine, either Pfizer or Moderna, over the single-shot Johnson & Johnson vaccine after a review of new CDC data on rare blood clots linked to J&J.
The vote was unanimous.
The rare blood clots are not a new safety concern and the vaccine has already become far less common in the U.S. after it was given an FDA warning label about the clotting condition. But more data that confirmed a slightly higher rate of clotting cases and deaths than was previously reported caused the CDC and FDA to take another look at the data this week.
The CDC has confirmed nine deaths and 54 cases from the severe clotting event, thrombosis with thrombocytopenia.
There could also be more cases and deaths because TSS is under-diagnosed and could be underreported, the CDC said.
The clotting is more common among women in their 30s and 40s but has been seen in adult men and women of all ages.
The experts said J&J should not be taken off the shelves and is still far more beneficial than not getting any vaccine at all.
-ABC News' Cheyenne Haslett